2006
DOI: 10.1111/j.1464-410x.2006.06290.x
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of type‐5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review

Abstract: This review examines the role of nitric oxide (NO) as a neurotransmitter involved in the central and peripheral control of ejaculation,

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
89
0
3

Year Published

2007
2007
2017
2017

Publication Types

Select...
8
1
1

Relationship

2
8

Authors

Journals

citations
Cited by 100 publications
(95 citation statements)
references
References 79 publications
(282 reference statements)
3
89
0
3
Order By: Relevance
“…In addition, reduced performance anxiety, because of better erection, and downregulation of the erectile threshold to a lower level of arousal could also account for the observed positive effects of SKGB. 40 Our results strongly support that the SKGB might be effective in men with PE and can help improve the quality of their sexual life. However, we would like to specify that this study did not aim at curing patients with PE because our patients were enrolled based on their erectile function only.…”
Section: Discussionsupporting
confidence: 71%
“…In addition, reduced performance anxiety, because of better erection, and downregulation of the erectile threshold to a lower level of arousal could also account for the observed positive effects of SKGB. 40 Our results strongly support that the SKGB might be effective in men with PE and can help improve the quality of their sexual life. However, we would like to specify that this study did not aim at curing patients with PE because our patients were enrolled based on their erectile function only.…”
Section: Discussionsupporting
confidence: 71%
“…Despite this theory, it is deemed unlikely that PDE-5 inhibitors have a significant role in the treatment of primary PE. This argument is supported by McMahon et al who reviewed all reports on the use PDE-5 inhibitors for PE that were published between (McMahon et al, 2006. The authors analysed 14 studies that reported on sildenafil, vardenafil and tadalafil.…”
Section: Phosphodiesterase Type 5 (Pde5) Inhibitorssupporting
confidence: 48%
“…However, perception of ejaculatory control and overall sexual satisfaction were slightly improved, and the refractory time to achieve a second erection after ejaculation was shortened. Nevertheless, the current level of evidence does not support a significant role of PDE-5 inhibitors in the treatment of PE with the exception of men with acquired PE secondary to comorbid erectile dysfunction (McMahon et al, 2006).…”
Section: Other Treatmentsmentioning
confidence: 95%